《美股業績》Novavax(NVAX.US)警今年收入存不確定性 盤後股價大跌26%
美國疫苗研發公司Novavax(NVAX.US)公布去年第四季虧損1.82億美元,銷售額為3.57億美元,不及市場預期,並警告今年收入、來自美國政府的資金以及與全球疫苗聯盟Gavi的未決仲裁存在重大不確定性,但截至去年底手頭現金為13.3億美元,有足夠資金為維持未來一年的營運。
在業績公布後,公司股價大跌26%至6.82美元。Novavax表示,美國政府並未將與公司的疫苗協議延長至今年12月之後,同時GAVI指控公司違反採購協議,公司有可能需要退還收到的大約7億美元資金。
Novavax表示,正計劃削減開支,可能包括裁員,將評估公司在全球的業務,希望合理化供應鏈、產品組合、公司結構以及基礎設施,但拒絕透過裁員數目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.